Cerebral venous thrombosis after COVID-19 vaccination: the role for endovascular treatment

Cerebral venous thrombosis (CVT) is a unique cause of stroke. Population-based studies demonstrate an incidence of clinically significant CVT of 1.3–1.5 per 100 000 per year.1 2 This may be an underestimated incidence, as these studies were not based on review of imaging and the often benign nature of this entity may lead to underdiagnoses. In the JNIS paper published by Cleaver et al,3 the authors describe their experience with endovascular treatment (EVT) in patients with cerebral venous sinus thrombosis in patients following COVID-19 vaccination. CVT-related stroke primarily affects young adult and middle-aged patients.4 5 Although initially blamed for having a 50% mortality based on autopsy series,6 more recent prospective multinational studies (International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)) have demonstrated a mortality rate of 8% in a cohort of 624 patients.7...
Source: Journal of NeuroInterventional Surgery - Category: Neurosurgery Authors: Tags: COVID-19 Commentary Source Type: research